NewAmsterdam Pharma (NAMS) EBITDA Margin (2023 - 2026)
NewAmsterdam Pharma (NAMS) reported EBITDA Margin of 1921.71% for Q1 2026, up 39276.0% on a YoY basis from N/an in Q1 2025, and up 99.07% sequentially from 206187.5% in Q4 2025.
NewAmsterdam Pharma (NAMS) EBITDA Margin (2023 - 2026) Analysis & Trends
NewAmsterdam Pharma (NAMS) has 4 years of EBITDA Margin data on file, last reported at 1921.71% in Q1 2026.
- For the quarter ending Q1 2026, EBITDA Margin rose 39276.0% year-over-year to 1921.71%; the trailing twelve-month figure through Mar 2026 stood at 953.59% (down 55111.0% YoY), and the FY2025 full-year result was 1002.9%, down 61599.0% from the prior year.
- EBITDA Margin rose to 1921.71% in Q1 2026, from 206187.5% in the prior quarter.
- In the past five years, EBITDA Margin ranged from a high of 85.89% in Q3 2024 to a low of 206187.5% in Q4 2025.
- A 4-year average of 18779.11% and a median of 2306.93% in 2024 frame the typical range for EBITDA Margin.
- Across the five-year window, EBITDA Margin jumped 602193 bps in 2024 and plunged 20584903 bps in 2025, its largest moves.
- Tracing NAMS's EBITDA Margin over 4 years: stood at 6360.4% in 2023, then soared by 95 bps to 338.47% in 2024, then slumped by 60818 bps to 206187.5% in 2025, then jumped by 99 bps to 1921.71% in 2026.
- Business Quant data shows NAMS's EBITDA Margin at 1921.71% in Q1 2026, 206187.5% in Q4 2025, and 15845.69% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 16.51% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 31.68% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | NewAmsterdam Pharma | 3.72 Bn | 3.72 Bn | - | -1,921.71% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1,921.71% |
| Dec 31, 2025 | -206,187.50% |
| Sep 30, 2025 | -15,845.69% |
| Jun 30, 2025 | -186.13% |
| Mar 31, 2025 | -2,314.47% |
| Dec 31, 2024 | -338.47% |
| Sep 30, 2024 | -85.89% |
| Jun 30, 2024 | -2,306.93% |
| Mar 31, 2024 | -3,960.17% |
| Dec 31, 2023 | -6,360.40% |
| Sep 30, 2023 | -1,685.07% |
| Jun 30, 2023 | -2,474.20% |
| Mar 31, 2023 | -461.85% |